Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy.
Rituximab and other monoclonal antibody therapies now in development have the potential to markedly impact the treatment of non-Hodgkin's lymphoma (NHL). These agents have significant single-agent activity, distinct mechanisms of action, and, in the case of rituximab and other unconjugated antibodies, favorable toxicity profiles that are nonoverlapping with the adverse effects associated with conventional chemotherapy. These properties may allow for the use of novel combination therapies with enhanced outcomes for patients. Systematic evaluation of rationally designed combinations through randomized, prospective trials is required to determine the clinical utility of these novel agents and combinations will live up to their potential.